By: IPP Bureau
Last updated : December 01, 2025 4:52 pm
StarGuide GX delivers ultra-high sensitivity and high-resolution imaging, enabling fast, confident diagnostics
GE HealthCare has announced CE Mark approval for its StarGuide GX system, a cutting-edge digital 4D SPECT/CT designed to deliver precision, efficiency, and versatility in molecular imaging.
The milestone will empower clinicians to expand research and personalize care across a growing range of tracers, including alpha emitters, according to the global med-tech company.
StarGuide GX arrives at a critical moment as the prevalence of complex diseases—cancer, Alzheimer’s, and cardiovascular conditions—drives demand for precision diagnostics and targeted therapies. The system allows clinicians to overcome energy-range limitations and capture tracers with unprecedented clarity, offering scalable solutions to manage rising patient volumes and increasingly complex treatment protocols.
“Our mission is to advance precision health by delivering technologies that meet the evolving needs of clinicians and patients,” said Jean-Luc Procaccini, President and CEO, Molecular Imaging and Computed Tomography, GE HealthCare.
“As nuclear medicine evolves to meet the demands of precision health, StarGuide GX is designed to help researchers and clinicians stay ahead, offering a whole new range of possibilities with one scanner. This innovation reflects our commitment to purposeful technology – supporting cases across care pathways and the practice of theranostics – to help both expand clinical capabilities and improve outcomes for patients worldwide.”
Powered by dual-sided CZT detector technology, StarGuide GX delivers ultra-high sensitivity and high-resolution imaging, enabling fast, confident diagnostics. Its patented dual collimator detector eliminates the need for manual or automated external exchanges, streamlining workflows and reducing physical strain. NVIDIA RTX accelerated computing further optimizes image reconstruction, cutting the time needed to generate scans.
The system’s versatility is striking: it can image all energy levels for general-purpose SPECT imaging, as well as investigational alpha therapies like Actinium-225, with outstanding image quality. Its ability to image closer to organs enhances resolution and quantitation—critical for treatment planning and monitoring.
“StarGuide GX is an innovation sure to prove valuable now and in the future,” said Erez Levy, Executive Director, Molecular Imaging, GE HealthCare. “Its ability to image alpha emitters and deliver accurate quantitation in short scan times could create new opportunities for clinicians to personalize treatment with great confidence. This technology holds the promise of expanding nuclear medicine’s research capabilities and clinical practice – with the ultimate goal of improving outcomes for patients across a wide range of conditions.”
Operational efficiency is another hallmark: fast scans, precise dynamic imaging, and reduced collimator exchange times help departments manage growing patient volumes with fewer resources. A lead-free, laser-printed collimator supports sustainability while maintaining exceptional image quality.
With StarGuide GX’s CE Mark, GE HealthCare strengthens its commitment to advancing nuclear medicine, equipping clinicians with tools for research, innovation, and personalized care. The system represents a significant step toward improving patient outcomes and shaping the future of precision health worldwide.